# 4,7 Dihydropyrazolo 3,4 b Pyridine derivatives.

## Abstract
Novel Ca blockers, 4,7 dihydropyrazolo 3,4 b pyridine derivatives having potent antihypertensive and coronary vaso dilating actions and useful in treatment for diseases in circula tory system, but without systole inhibitory action.

## Claims
What is claimed is 1. A 4,7 dihydropyrazolo 3,4 b pyridine derivative represented by the formula EMI58.1 wherein Rl is alkyl of 5 or sore carbons, cycloalkyl which may be substituted, cycloalkylalkyl, alkoxyalkyl, cycloalkyloxyalkyl, aryloxyalkyl, alkylthioalkyl, cycloalkylthioalkyl, phenylthioalkyl, cono or di alkylamino alkyl, tetrahydrofurylalkyl, aralkyl which say be substituted by one or two substituents, N benzylpyrrolidinyl, or N benzylpiperidinyl R2 is alkyl and R3 is cycloalkyl or cycloalkylalkyl and the acid addition salts thereof. 2. A compound claimed in dais 1, 3 thienyl ethyl 3 cyclopentyl 1,6 dimethyl 4 2 nitrophenyl 4,7 dihydropyrazolo 3, 4 bjppridine 5 carboxylate. 3. A compound claimed in clain 1, isopropylthioethyl 3 cyclopentyl 1, 6 diraethyl 4 2 nitrophenyl 4, 7dihydropyrazolo 3,4 b pyridine 5 carboxylate. 4. A compound claimed in claim 1, cyclopentyloxyethyl 3 cyclopentyl 1, 6 dimethyl 4 2 nitrophenyl 4, 7dihydropyrazolo 3, 4 b pyridine 5 carboxylate. 5. A compound claimed in claim 1, methylthioethyl 3cyclopentyl l, 6 dimethyl 4 2 nitrophenyl 4, 7dihydropyrazolo 3, 4 b pyridine S carboxylate. 6. A compound claimed in claim 1, phenoxyethyl 3cyclopentyl 1, 6 dimethyl 4 2 nitrophenyl 4, 7dihydropyrazolo 3, 4 b pyridine 5 carboxylate. 7. A compound claimed in claim 1, phenethyl 3 cyclopentyl1, 6 dimethyl 4 2 nitrophenyl 4, 7 dihydropyrazolo 3, 4 b pyridine 5 carboxylate. 8. A compound claimed in claim 1, methoxyethyl 3cyclohexyl l, 6 dimethyl 4 2 nitrophenyl 4, 7dihydropyrazolo 3, 4 b pyridine 5 carboxylate. 9. A compound claimed in claim 1, 2 tetrahydrofurylmethyl 3 cyclopentyl 1, 6 dimethyl 4 2 nitrophenyl 4, 7 dihydropyrazolo 3, 4 b pyridine S carboxylate. 10. A compound claimed in claim 1, phenylthioethyl 3cyclopentyl l, 6 dimethyl 4 2 nitrophenyl 4, 7dihydropyrazolo 3, 4 b pyridine 5 carboxylate. 11. A compound claimed in claim 1, n pentyl 3 cyclopentyl 1, 6 dimethyl 4 2 nitrophenyl 4, 7 dihydropyrazolo 3, 4 b pyridine 5 carboxylate. 12. A compound claimed in claim 1, cyclopentylthioethyl 3 Cyclopentyl 1, 6 dimethyl 4 2 nitrophenyl 4,7dihydropyrazolo 3, 4 b pyridine 5 carboxylate. 13. A compound claimed in claim 1, cyclopentylethyl 3cyclopentyl 1, 6 dimethyl 4 2 nitrophenyl 4, 7dihydropyrazolo 3, 4 b pyridine 5 carboxylate. 14. A process for production of 4,7 dihydropyrazolo 3,4 b pyridine derivatives represented by the formula EMI60.1 wherein Rt, R2 and R3 have the same meanings as defined above, respectively, which comprises reacting a compound represented by the formula EMI60.2 wherein R1 has the same meaning as defined above, with a compound represented by the formula EMI61.1 wherein R2 and R3 have the same meanings as defined above, respectively. 15. An agent for treating cardiovascular diseases, comprising at least one substance selected from 4,7dihydropyrazolo 3,4 b pyridine derivatives represented by the formula EMI61.2 wherein Rl, R2 and R3 have the same meanings as defined above, respectively, and the pharmaceutically acceptable acid addition salts thereof.

## Description
4,7 DIHYDROPYRAZOLO 3,4 b PYRIDINE DERIVATIVES BACKGROUND OF THE INVENTION 1 Field of the Invention The compounds this invention provides are novel Cablocker type cardiovascular agents having potent antihypertensive and coronary vasodilating effects, and useful in treatment for cardiovascular diseases such as angina pectoris, hypertension, cerebrovascular dysfunction, arrhythmia or the like.2 Prior Art. Compounds having Ca blocking effect have commonly been used for treatment of cardiovascular diseases such as angina pectoris, hypertention, cerebrovascular dysfunction, arrhythmia or the like, and have become well known because of their high efficacy. In particular, a series of 1, 4dihydropyridine derivatives have been investigated extensively and developed as Ca blocker. Examples of useful Ca blockers are Nifedipine U.S. Patent Nos. 3,485,847 and 3, 644, 627 ,Nisoldipine Japanese Patent Publication No. 56 47185 , 2amino 1,4 dihydropyridine derivatives Jap.Pat.Pub. No. 5720306 , Nicardipine Jap.Unexamined Pat.Pub. No. 49 109384 , 2 pyridyl 1,4 dihydropyridine derivatives Jap. Unexam. Pat. Pub. No. 54 48796 , 2 methyldihydropyridine derivatives Jap. Unexam. Pat.Pub. No. 55 62065 and the like. Some examples of pyrazolodihydropyridine derivatives, the production thereof and their Ca blocking action are disclosed in Jap.Pat.Application Nos. 57 176763 and 58 166258 by the present inventors. SUMMARY The present invention relates to novel 4,7dihydropyrazolo 3,4 b pyridine derivatives and production thereof. More particularly it relates to 4,7dihydropyrazollo 3,4 b pyridine derivatives represented by the formula EMI2.1 wherein Rl is alkyl of 5 or lore carbons, cycloalkyl which say be snbstituted, cycloalkylalkyl, alkoxyalkyl, cycloalkyloxyalkyl, aryloxyalkyl, alkylthioalkyl, cycloalkylthioalkyl, phenylthioalkyl, nono or di alkylaiino alkyl, tetrahydrofurylalkyl, aralkyl which may be substituted by one or two substituents, N benzylpyrrolidinyl, or N benzylpiperidinyl R2 is alkyl and R3 is cycloalkyl or cycloalkylalkyl and a process for the production of 4,7dihydropyrazolo 3,4 b pyridine derivatives represented by the formula EMI3.1 wherein Rl, R2 and R3 each has the same meaning as defined above, which comprises reactingla compound represented by the formula EMI3.2 wherein RI has the same meaning as defined above, with a compound represented by the formula EMI3.3 wherein 22 and R3 each has the sale meaning as defined above. Incidentally, the compounds of this invention have the advantage that they have no systole inhibitory action as an adverse reaction usually seen in the use of the analogous known compounds. The objective conpounds I of this invention are prepared through the Michael addition between heterocyclic aries and a, B unsaturated ketones accompanied by cyclization reaction. DESCRIPTION OF THE PREFERRED ENBODIMENT In the definition in the formula I m , alkyl of five or more carbons means straight or branched chain C5 C, alkyl, such as n pentyl, iso pentyl, sec pentyl, neo pentyl, tert pentyl, n hexyl, iso hexyl, sec hexyl, neo hexyl, terthexyl, n heptyl, iso heptyl, sec heptyl, neo heptyl, tertheptyl, n octyl, iso octyl, sec octyl and the like. Cycloalkyl which say be substituted means substituted or unsubstituted C, C, cycloalkyl, wherein the substituent includes lower alkyls such as methyl, ethyl, n propyl, isopropyl, n butyl, iso butyl, sec butyl, tert butyl, n pentyl, iso pentyl, neo pentyl, tert pentyl and the like for example, cyclobutyl, cyclopentyl, cyclohexyl, 2 iso propyl 4 methyl cyclohexyl and the like are exemplified as the cycloalkyl. Cycloalkylalkyl means Cl C, alkyl substituted by C3 C, cycloalkyl, wherein C3 C7 cycloalkyl includes cyclopropyl, cyclobutyl, cyclohexyl, cycloheptyl or the like, and C, C, alkyl includes methyl, ethyl, propyl, butyl or the like. Alkoxyalkyl means Cl C, alkyl substituted by Cl C, alkoxy, wherein Cl C, alkoxy includes methoxy, ethoxy, npropoxy, iso propoxy, n butoxy, iso butoxy, tert butoxy or the like, and C, C, alkyl includes the same examples listed above. Cycloalkyloxyalkyl means Cl C, alkyl substituted byC, C, cycloalkyloxy, wherein C, C, cycloalkyloxy includes cyclobutyloxy, cyclopentyloxy, cyclohexyloxy or the like, and Cl C, alkyl includes the same as listed above. Aryloxyalkyl means Cl C, alkyl substituted by aryloxy, particularly phenoxy, wherein C C, alkyl includes the same as listed above. Alkylthioalkyl means Cl C, alkyl substituted by C C, alkylthio, wherein C, C, alkylthio includes methylthio, ethylthio, n propylthio, iso propylthio, n butylthio, isobutylthio, sec butylthio, tert butylthio or the like, and C1 C, alkyl includes the same as listed above. Cycloalkylthioalkyl means Cl C, alkyl substituted byC, C, cycloalkylthio, wherein C, C, cycloalkylthio includes cyclobutylthio, cyclopentylthio, cyclohexylthio, cycloheptylthio or the like, and Cl C, alkyl includes the same as listed above. Phenylthioalkyl means Cl C, alkyl substituted by phenylthio, wherein C1 C4 alkyl includes the same as listed above. Mono or di alkylamino alkyl means C1 C4 alkyl substituted by C1 C4 mono alkylamino or C2 C8 di alkylamino, wherein C, C, mono alkylamino includes methylamino, ethylamino, n propylamino, iso propylamino, n butylaaino, iso butylanino, sec butylanino, tert butylamino and the like andC2 C8 dialkylamino includes dimethylamino, methylethylamino, methyl n propyl amino, methyl iso propyl amino, diethylamino, aethyl n butyl amino, aethyl iso butyl amino, methyl sec butyl amino, methyl tert butyl amino, ethyl n propyl amino, ethyl iso propyl aiino, ethyl n butyl amino, ethyl isobutyl amino, ethyl sec butyl amino, ethyl tert butyl amino, dipropylamino, n propyl n butyl amino, n propyl iso butyl amino, n propyl sec butyl anino, n propyl tertbutyl amino, iso propyl n butyl amino, iso propyl isobutyl amino, iso propyl sec butyl amino, iso propyl tertbutyl amino, dibutyla ino and the like, and C1 C4 alkyl includes the same as listed above. Tetrahydrofurylalkyl means 2 tetrahydrofuryl C, C, alkyl or 3 tetrahydrofuryl C, C, alkyl, wherein C C, alkyl includes the same as listed above. Aralkyl which may be substituted by one or two substituents means substituted or unsubstituted C, C, aralkyl, wherein the substituents include halogens such as fluoro, chloro, bromo and iodo and C, C, alkoxy listed above. More specifically, benzyl, phenetyl, 3phenylpropyl, tolylmethyl, 4 fluorophenethyl, 4 chlorophenethyl, 4 bromophenethyl, 4iodophenethyl, 3,4 dimethoxyphenethyl, 1 methoxy 2 phenethyl and the like are exemplified as the aralkyl. In the definition of R2, alkyl means C C, alkyl as exemplified above, and in that of R3, cycloalkyl means C, Cs cycloalkyl, which includes cyclobutyl, cyclopentyl, cyclohexyl and the like. The compound I of the present invention can, as shown in the following scheme, be readily produced by the reaction of alpha , ss unsaturated ketone reagent E with a 5aminopyrazole m , EMI7.1 wherein R1, R2 and R3 each has the same meaning as identified above. The reaction may be accomplished in the absence or presence of any solvent. Such a solvent as employed for this reaction includes alcohols such as methanol, ethanol, isopropanol, tert butanol, ethylene glycol and the like hydrocarbons such as benzene, toluene, xylene and the like ethers such as ether, tetrahydrofuran, dioxane, glyme, diglyme and the like halogeno hydrocarbons such as dichloro ethane, chloroforu, dichloroethane, carbon tetrachloride and the like esters such as ethyl acetate acetic acid dimethylformaminde pyridine and the like. An acid, an organic base or the like is employed as a catalyst, if necessary.Such an acid includes inorganic acids e.g., sulfuric acid, hydrochloric acid, phosphoric acid and the like para toluenesulfonic acid, acetic acid, formic acid and the like as an organic acid and boron trifluoride, zinc chloride, aluminium chloride, magnesium chloride, tin chloride and the like as a Lewis acid. Such a base includes organic base catalysts e.g., triethylamine, pyridine, pyrrolidine, piperidine and the like. The reaction is completed after a few hours or a few days at room temperaturel 30 C or under heating 30 100 C . The starting compounds, 5 aminopyrazole and a, . ss unsaturated ketone reagents, both of which are employed in the reaction, say be prepared in the manners as shown below, respectively. i Preparation of 5 ainopyrazole M A 5 aminopyrazole N can be produced according to the reaction sequence as shown below. In other words, it can be prepared in a high yield by the cyclization of a hydrazine N with a ss ketonitrile V . Processes for the production of the compounds N are disclosed in the Jap. Pat. Application Nos. 57 176763 and 58166258 by the present inventors.EMI9.1 wherein R2 and R3 each has the same meaning as defined above,R represents halogen or an ester residue, and M represents an alkali metal. The ss ketonitriles V are prepared through the reaction of an acid chloride or an ester with an alkali metal salt of acetonitrile. ii Preparation of alpha , ss unsaturated ketone reagents I a , ss Unsaturated ketone reagents U are prepared, as shown in the following scheme, by the condensation reaction of an aldehyde N with an acetoacetic ester IX the manner of the reaction is desclosed in j. Chem Soc., 81, 1212 1902 Che7 Ber., 29, 172 1896 Ann., 218, 170 1883 J. Ches Soc., 3092 1962 .EMI10.1 wherein Rl has the sae meaning as defined above. The acetoacetic esters are prepared, in the presence of an acid hydrochloric acid, sulfuric acid, phospholic acid and the like or base pyridine, pyrrolidine, piperidine and the like catalyst, through the reaction of a diketene X with an alcohol XI . The compounds of the present invention, which are prepared by the reaction of the above obtained alpha , , ss ss unsaturated ketone reagents I with a 5 aminopyrazole N , are listed below. 1 2 Methoxyethyl 3 cyclopentyl 1,6 dimethyl 4 2nitrophenyl 4,7 dihydropyrazolo 3,4 b pyridine 5 carboxylate, 2 2 Methoxyethyl 3 cyclopentyl 1,6 dimethyl 4 3 nitrophenyl 4, 7 dihydropyrazolo 3,4 b pyridine 5 carboxylate, 3 2 Methoxyethyl 3 cyclohexyl 1,6 dimethyl 4 2 nitrophenyl 4,7 dihydropyrazolo 3,4 b pyridine 5 carboxylate, 4 2 Methoxyethyl 3 cyclopentylmethyl 1,6 dimethyl 4 2nitrophenyl 4,7 dihydropyrazolo 3,4 b pyridine 5 carboxylate, 5 2 Isopropoxypropyl 3 cyclopentyl 1,6 dimethyl 4 2nitrophenyl 4,7 dihydropyrazolo 3,4 b pyridine 5 carboxylate, 6 2 Cyclopentyloxyethyl 3 cyclopentyl 1,6 dimethyl 4 2 nitrophenyl 4,7 dihydropyrazolo 3, 4 b pyridine 5 carboxylate, 7 2 Cyclohexyloxyethyl 3 cyclopentyl 1,6 dimethyl 4 2 nitrophenyl 4,7 dihydropyrazolo 3, 4 b pyridine 5carboxylate, 8 2 Tetrahydrofurylmethyl 3 cyclopentyl 1,6 dimethyl 4 2 nitrophenyl 4, 7 dihydropyrazolo 3, 4 b pyridine 5 carboxylate, 9 2 Phenoxyethyl 3 cyclopentyl l, 6 dimethyl 4 2nitrophenyl 4, 7 dihydropyrazolo 3, 4 b pyridine 5 carboxylate, 10 2 Phenoxyethyl 3 cyclopentyl l, 6 dimethyl 4 3nitrophenyl 4, 7 dihydropyrazolo 3, 4 b pyridine 5 carboxylate, 11 2 Phenoxyethyl 3 cyclohexyl l, 6 dimethyl 4 2nitrophenyl 4, 7 dihydropyrazolo 3, 4 b pyridine 5 carboxylate, 12 2 Methoxyethyl 3 cyclopentyl 1,6 dimethyl 4 2nitrophenyl 4,7 dihydropyrazolo 3,4 b pyridine 5 carboxylate, 13 2 dimethylaminopropyl 3 cyclopentyl 1,6 dimethyl 4 2nitrophenyl 4,7 dihydropyrazolo 3,4 b pyridine 5carboxylate, 14 N Benzylpyrrolidin 3 yl 3 cyclopentyl 1,6 dimethyl 4 2 nitrophenyl 4,7 dihydropyrazolo 3,4 b pyridine 5carboxylate, 15 N Benzylpyrrolidin 4 yl 3 cyclopentyl 1,6 dimethyl 4 2 nitrophenyl 4,7 dihydropyrazolo 3,4 b pyridine 5carboxylate, 16 n Pentyl 3 cyclopentyl 1,6 dimethyl 4 2 nitrophenyl 4,7 dihydropyrazolo 3,4 b pyridine 5 carboxylate, 17 Phenethyl 3 cyclopentyl 1,6 dixethyl 4 2 nitrophenyl 4,7 dihydropyrazolo 3,4 b pyridine 5 carboxylate, 18 4 Chlorphenethyl 3 cyclopentyl 1,6 dimethyl 4 2nitrophenyl 4,7 dihydropyrazolo 3,4 b pyridine 5carboxylate, 19 3,4 Dimethoxyphenethyl 3 cyclopentyl 1,6 dimethyl 4 2nitrophenyl 4, 7 dihydropyrazolo 3, 4 b pyridine 5 carboxylate, 20 1 Methoxy 2 phenylethyl 3 cyclopentyl 1,6 dimethyl 4 3 nitrophenyl 4,7 dihydropyrazolo 3,4 b pyridine 5carboxylate, 21 2 Isopropyl 4 methylcyclohexyl 3 cyclopentyl 1, 6dimethyl 4 3 nitrophenyl 4, 7 dihydropyrazolo 3, 4 b pyridine 5 carboxylate, 22 2 Phenylthioethyl 3 cyclopentyl 1, 6 dimethyl 4 2nitrophenyl 4, 7 dihydropyrazolo 3, 4 b pyridine 5 carboxylate, 23 2 Isopropylthioethyl 3 cyclopentyl 1,6 dimethyl 4 2nitrophenyl 4,7 dihydropyrazolo 3,4 b pyridine 5carboxylate, 24 2 Cyclopetnylthioethyl 3 cyclopentyl 1,6 dimethyl 4 2 nitrophenyl 4, 7 dihydropyrazolo 3, 4 b pyridine 5 carboxylate, 25 2 Cyclopentylethyl 3 cyclopentyl 1, 6 dimethyl 4 2nitrophenyl 4, 7 dihydropyrazolo 3, 4 b pyridine 5 carboxylate, 25 Cyclohexylmethyl 3 cyclopentyl 1,6 dimethyl 4 2nitrophenyl 4, 7 dihydropyrazolo 3, 4 b pyridine 5 carboxylate, 27 Cyclopentyl 3 cyclopentyl 1, 6 dimethyl 4 2 nitrophenyl 4, 7 dihydropyrazolo 3, 4 b pyridine 5 carboxylate, 28 Cyclohexyl 3 cyclopentyl 1, 6 dimethyl 4 2nitrophenyl 4, 7 dihydropyrazolo 3, 4 b pyridine 5 carboxylate. In addition, the acid addition salts, which can be obtained froa the above listed compounds, can be used as an active ingredient in this invention. Some examples of the acids capable to form such salts are inorganic acids such as hydrohalogenic acid hydrochloric acid, hydrobromic acid or the like , sulfuric acid, nitric acid, phospholic acid or the like and organic acids such as acetic acid, propionic acid, oxalic acid, salonic acid, succinic acid, glutaric acid, adipic acid, salic acid, saleic acid, fumaric acid, citric acid, benzoic acid, siethanesulfonic acid or the like. Effect and Use The novel compounds of the present invention have the advantage that they have excellent antihypertensive and coronary vasodilating actions derived from Ca blocking action, but have no systole inhibitory action which is one of adverse reactions and have been a defect of the conventional Cablockers. The biological tests of the following compounds were perforeed as explained below. Compounds Tested A Nifedipine B 2 Methoxyethyl 3 cyclopentyl 1,6 dimethyl 4 2 nitrophenyl 4,7 dihydropyrazolo 3,4 b pyridine 5 carboxylate C 2 Methoxyethyl 3 cyclopentyl 1,6 dimethyl 4 3 nitrophenyl 4,7 dihydropyrazolo 3,4 b pyridine 5 carboxylate D 2 Methoxyethyl 3 cyclopentyl 1,6 dimethyl 4 2nitrophenyl 4,7 dihydropyrazolo 3,4 b pyridine 5 carboxylate E 2 Methoxyethyl 3 cyclopentylmethyl 1,6 dimethyl 4 2nitrophenyl 4,7 dihydropyrazolo 3,4 b pyridine 5 carboxylate F 3 Isopropoxypropyl 3 cyclopentyl 1,6 dimethyl 4 2nitrophenyl 4,7 dihydropyrazolo 3,4 b pyridine 5 carboxylate G 2 Cyclopentyloxyethyl 3 cyclopentyl 1,6 dimethyl 4 2 nitrophenyl 4,7 dihydropyrazolo 3,4 b pyridine 5 carboxylate H 2 Tetrahydrofurylmethyl 3 cyclopentyl 1,6 dimethyl 4 2 nitrophenyl 4,7 dihydropyrazolo 3,4 b pyridine 5carboxylate I 2 Phenoxyethyl 3 cyclopentyl 1,6 dimethyl 4 2 nitrophenyl 4,7 dihydropyrazolo 3,4 b pyridine 5 carboxylate J 2 Methylthioethyl 3 cyclopentyl 1,6 dimethyl 4 2nitrophenyl 4,7 dihydropyrazolo 3,4 b pyridine 5 carboxylate K Phenethyl 3 cyclopentyl 1,6 dimethyl 4 2 nitrophenyl 4,7 dihydropyrazolo 3,4 b pyridine 5 carboxylate L 4 Chlorophenethyl 3 cyclopentyl 1,6 dimethyl 4 3 nitrophenyl 4,7 dihydropyrazolo 3,4 b pyridine 5 carboxylate M 3,4 Dimethoxyphenethyl 3 cyclopentyl 1,6 dimethyl 4 3nitrophenyl 4,7 dihydropyrazolo 3,4 b pyridine 5 carboxylate Test Method 1 Antihypertensive Action Female Spontaneously Hypertensive Rats hereinafter referred to as SHR with 160 mmHg of systolic pressure were employed without anaesthetization. The systolic pressure was, after SHRs were kept warm at 50 C for 2 3 minutes, bloodlessly measured by the tail cuff method Japan J.Pharmacol, 28, 617 1978 using a Physiograph and an Electrosphygiosanometer DMP 4B, PE 300, Narco Biosystens, Inc., Houston . Each compound was interaperitoneally administered to SHR at a dose of 3 Mg per kilograms. 2 Coronary Vasodilating Action and Systole InhibitoryAction Guinea pigs with 400 800g of body weight were strongly hit on their heads and the cartoid artery of eachGuinea pigs was cut down in order to sake them bloodless. The heart was isolated and perfused with at a constant pressure 50 cm H2O by the Langendorff method Basic Pharmacology BR Therapeutics, 9 4 , 181 1981 . Krebs Ringer bicarbonate solution 27 containing 0.5Z defibrinated blood was employed as a perfusate, into which a mixed gas of 95X oxygen and 5 carbon dioxide was continuously introduced. The flowing perfusate was led into a drop counter, and the changes of the flow i.e. increase and decrease are regarded as the respective indications for coronary vasodilation and vasoconstriction.The isomeric contraction of apex and the number of drops of the coronary perfusate were recorded on a Recticorder RJG 3006, Nihon Koden by way of an F D Pick up SB 1T, NihonKoden . Each of the test compounds at a dose of 0.1 g g was administered through the short rubber tube connecting the aorta and the cannula. Results Antihypertensive action is shown in a maximal decrease of blood pressure, i.e., a maximum difference between systolic pressures after and before the administration of the test compound along with which the duration period is also shown. Coronary vasodilating action is shown in changes of the quantiy of the perfusate, and systole inhibitory action is shown in those of inotropic tension. Table 1 Antihypertensive action, coronary vasodilating action and systole inhibitory action EMI17.1 tb SEP Maximum SEP Duration SEP of SEP Perfusion SEP Change SEP of SEP Contrac tb Compounds SEP Hypertension SEP Effect SEP Flow SEP Change SEP tile SEP Tention tb SEP mmHg SEP hours SEP SEP SEP tb SEP A SEP 45 SEP 6 SEP 38 SEP 15 tb SEP B SEP 45 SEP 6 SEP 28 SEP 0 tb SEP C SEP 36 SEP 6 SEP 15 SEP 0 tb SEP D SEP 65 SEP 6 SEP 32 SEP 0 tb SEP E SEP 26 SEP 6 SEP 20 SEP 0 tb SEP F SEP 53 SEP 6 SEP 65 SEP 0 tb SEP G SEP 53 SEP 6 SEP 67 SEP 0 tb SEP H SEP 0 SEP SEP SEP µ34 SEP 0 tb SEP I SEP 74 SEP 6 SEP 43 SEP 0 tb SEP J SEP 20 SEP 6 SEP 68 SEP 0 tb SEP K SEP 75 SEP 6 SEP 63 SEP 0 tb SEP L SEP 74 SEP 6 tb SEP H SEP 86 SEP 6 tb Since the compounds of this invention, as clearly seen from the above listed results, show the highly antihypertensive and coronary vasodilating actions but no systole inhibitory action, they can be used as a cardiovascular agent with lesser adverse reactions to human or anjials. The compounds of this invention and the acid addition salts thereof can orally or pareterally be administered to human or animals and can be manufactured in various foriulations in compliance with the usage. They, for instance, can be in a forailation of tablets, capsules, pills, granules, fine granules, aqueous solutions, emulsions or the like. In the course of the formulation, conventional carriers or diluents such as lactose, sucrose, starch, cellulose, talc, magnesium stearate, magnesium oxide, calcium sulfate, powdered gac arabic, gelatin, sodium arginate, sodium benzoate, stearic acid and the like are employed.Injections used may be in a formulation of a solution with distilled water, saline solution, Ringer solution or the like, or 9 suspension in sesame oil. The compounds of this invention may be administered to an adult orally at a dose of about 1 50 mg a day, or intravenously at about 0.5 20 ig a day. The present invention is further described in the following Examples and Preparations. EXAMPLE 1Preparation of 2 methoxyethyl 3 cyclopentyl 1 ,6 dimethyl 4 2 nitrophenyl 4,7 dihydropyrazolol3,4 b pyridine 5 carboxylate 3.EMI19.1 In 6 ml of tert butÅanol are dissolved 0.90 g 3.05 mMol. of 2 methoxyethyl 2 nitrobenzylideneacetoacetate 1 and 0.50 g 3.05 mMol. of 3 cyclopentyl 5 amino 1 methylpyrazole 2, and the solution is allowed to react at 80O for 3 hours, then evaporated under reduced pressure. The resulting residue is crystallized from ether, filtered and washed with a small amount of ether to give the 1.15 g of the titled compound 3.This is recrystallized from ethanol to give 0.92 g of yellow prises in 59.6X yield, mp. 196 1980C. Elementary Analysis Calcd. for C23H25N4O5 C, 62.71 H, 6.41 N, 12.72. Found X C, 62.69 H, 6.20 N, 12.82.IR Nujol max 3260 NH , 1690 C O , 1360 NIO2 cm 1.NMR CDCl3 8 pp 0.97 2.03 8H, m , 2.33, 3.27, 3.63 3H x 3, s , 2.92 1H, m , 3.51 28, m , 4.13 2H, m , 5.92 1H, s , 6.677 1H, br, s , 7.00 7.73 4H, m . EXAMPLES 2 33EMI20.1 wherein R , Rê and RS each has the same meaning as defined above. A solution of compounds I and II in a solvent is allowed to react in nitrogen atmosphere at room temperature or under heating and then evaporated. The residue is crystallized from ether, or chromatographed on silica gel to give the objective compound I . This, if needed, is purified by recrystallization. The objective compounds of the present invention can, which are listed in the following Table 2, be prepared in the manner commonly described above. Details of the reaction conditions are summarized in Table 3. Additionally, recrystallization solvents, appearance crystal form, color , molecular formula and the result by elemental analysis in each compound or the acid addition salt are summarized in Table 4 and the IR and NMR spectrum data are shown in Table 5. EMI22.1 Table 2 No. 1 EMI22.2 tb rarpl SEP RI SEP R2 SEP R3 SEP Position SEP Yield tb SEP No. SEP of SEP NOa SEP tb SEP 3 SEP CE2CE20CE3 SEP 1 SEP 1 SEP 2 SEP 72.1 tb SEP 4 SEP 1. SEP CH2 a SEP 51.5 tb SEP 5 SEP 2CE2C820C SEP SEP 3 SEP w SEP SEP 75.4 tb SEP 6a SEP H2CK2O SEP 1 SEP 1 SEP 1 SEP 77 0 tb SEP 7a SEP CK2CE20 SEP 4 SEP 78.9 tb 8 SEP CE2 SEP I SEP SEP 1 SEP 81 5 tb SEP gb SEP CE2CH20 SEP 4 SEP w SEP . SEP 81.9 tb SEP lOa SEP w SEP I SEP SEP 3 SEP 89.7 tb SEP l7a SEP I SEP w SEP SEP 2 SEP 81.7 tb SEP 12b SEP 2 SEP 2 SEP 3 SEP 31.5 tb SEP cH SEP 42.3 tb SEP 13b SEP CE2C SEP 2 SEP 2 SEP SEP 3 SEP w tb SEP 3 tb 14 SEP SEP C2 SEP 1 SEP 1 SEP w SEP 60.7 tb SEP 15b SEP CkCR SEP I SEP 4 SEP 54.7 tb SEP 16a SEP CE2 i CE3 SEP w SEP w SEP 1 SEP 72 8 tb SEP 17 SEP 2 SEP 2 SEP 4 SEP CHaCR2 11 SEP 67.2 tb Table 2 No.2 EMI23.1 tb Example SEP R1 SEP R2 SEP R3 SEP Position SEP Yield tb SEP No. SEP . SEP of SEP N02 SEP tb SEP ôt SEP CH2cH2 SEP Cl SEP cH SEP 2 SEP 76. SEP O tb SEP SEP c2cH2R3 SEP ml SEP u SEP 74.8 tb SEP 1 SEP 3 tb SEP OCR tb SEP 20 SEP CRCR32 SEP S SEP U SEP 3 SEP 96.2 tb SEP 21a SEP oH3 SEP n SEP n SEP n SEP 75 SEP 6 SEP 9 tb SEP cE3 tb SEP 22a SEP cR2cR2s SEP U SEP 2 SEP 2 SEP 71.4 tb SEP 23d SEP CH2CH2S Cf3 SEP I SEP w SEP n SEP 77.5 tb SEP 3 tb SEP 24 SEP CH2CH2S a SEP n SEP n SEP n SEP 77.8 tb SEP 23a SEP ci2ar2 SEP U SEP U SEP 72.8 tb SEP 26a SEP CH20 SEP n SEP n SEP n SEP 76.8 tb SEP 27 so SEP U SEP I SEP n SEP n SEP 67.0 tb SEP 28t SEP 0 SEP 64.3 tb a Hydrochloride b Oxalate Table 2 No. 3 EMI24.1 Example SEP R1 SEP Rê SEP R SEP Position SEP Yield tb No. SEP of SEP NO2 SEP tb 29a SEP Cl SEP SEP SEP 3 SEP 73.2 tb 30a SEP OMe SEP SEP SEP SEP 56.6 tb SEP OMe tb 31a SEP Cl SEP SEP SEP SEP 58.2 tb SEP Cl tb 32a SEP Br SEP SEP SEP SEP 70.8 tb 33a SEP SEP SEP SEP SEP 67.8 tb SEP CF3 tb EMI25.1 Table 3 No. 1 EMI25.2 tb SEP Amount SEP used SEP g SEP mmol SEP Solvent SEP Reaction SEP Reaction tb Example SEP Temp. SEP Time tb SEP No. SEP ml SEP C SEP hrs. tb SEP Compd. SEP II SEP Compd. III tb SEP 2 SEP 0.88 3.01 SEP 0.50 3.05 SEP t butanol SEP 5 SEP 80 SEP 3 tb SEP 3 SEP 0.88 3.01 SEP 0.54 3.01 SEP SEP 6 SEP 80 SEP 3 tb SEP 4 SEP 0.88 3.01 SEP 0.54 3.01 SEP i isopropanol SEP 2 SEP 70 SEP 72 tb SEP 5 SEP 0.67 2.0 SEP 0.33 2.0 SEP SEP 2 SEP 80 SEP 15 tb SEP 6 SEP 0.57 1.64 SEP 0.27 1.64 SEP SEP 2 SEP 80 SEP 24 tb SEP 7 SEP 1.04 2.87 SEP 0.47 2.87 SEP SEP 10 SEP 80 SEP 20 tb SEP 8 SEP 0.64 2.0 SEP 0.33 2.0 SEP SEP 2 SEP 80 SEP 24 tb SEP 9 SEP 0.71 2.0 SEP 0.33 2.0 SEP SEP 2 SEP 80 SEP 24 tb SEP 10 SEP 1.00 2.81 SEP 0.47 2.87 SEP SEP 10 SEP 80 SEP 3 tb SEP 11 SEP 0.90 2.53 SEP 0.45 2.53 SEP SEP 9 SEP 80 SEP 20 tb SEP 12 SEP 0.62 2.0 SEP 0.33 2.0 SEP SEP 2 SEP 80 SEP 24 tb SEP 13 SEP 0.64 2.0 SEP 0.33 2.0 SEP SEP 4 SEP 80 SEP 18 tb SEP 14 SEP 2.01 5.08 SEP 0.84 5.09 SEP SEP 5 SEP 80 SEP 17 tb SEP 15 SEP 1.01 2.46 SEP 0.41 2.48 SEP SEP 15 SEP 80 SEP 19 tb SEP 16 SEP 0.89 2.92 SEP 0.48 2.92 SEP SEP 9 SEP 80 SEP 19 tb SEP 17 SEP 0.68 2.0 SEP 0.33 2.0 SEP SEP 2 SEP 80 SEP 16 tb SEP 18 SEP 0.95 2.54 SEP 0.42 2.54 SEP SEP 10 SEP 80 SEP 20 tb Table 3 No.2 EMI26.1 tb SEP Amount SEP g SEP mmol SEP Solvent SEP Reaction SEP Reaction tb Example SEP Used SEP Temp. SEP Time tb SEP No. SEP ml SEP C SEP hrs. tb SEP Compd. SEP II SEP Compd. III tb SEP 19 SEP 1.13 2.82 SEP 0.47 2.82 SEP i propanol SEP 10 SEP 80 SEP 20 tb SEP 20 SEP 3.39 9.19 SEP 1.52 9.19 SEP t butanol SEP 10 SEP 80 SEP 2 tb SEP 21 SEP 4.09 10.9 SEP 1.81 10.9 SEP SEP 15 SEP 80 SEP 3 tb SEP 22 SEP 1.0 SEP 2.7 SEP 0.45 2.7 SEP SEP 5 SEP 80 SEP 16 tb SEP 23 SEP 0.92 2.72 SEP 0.45 2.7 SEP i propanol SEP 5 SEP 80 SEP 20 tb SEP 24 SEP 1.08 2.96 SEP 0.49 2.96 SEP SEP 5 SEP 80 SEP 20 tb SEP 25 SEP 1.05 3.15 SEP 0.52 3.15 SEP SEP 5 SEP 80 SEP 20 tb SEP 26 SEP 1.33 4.0 SEP 0.66 4.0 SEP t butanol SEP 10 SEP 80 SEP 20 tb SEP 27 SEP 1.02 3.34 SEP 0.55 3.34 SEP i propanol SEP 5 SEP 80 SEP 20 tb SEP 28 SEP 1.01 3.19 SEP 0.53 3.19 SEP SEP 5 SEP 80 SEP 19 tb Table 3 No. 3 EMI27.1 Example SEP Amount SEP used SEP g SEP mmol SEP Solvent SEP Reaction SEP Reaction tb SEP Temp. SEP Time tb No. SEP Compd. SEP II SEP Compd. III SEP ml SEP C SEP hrs. tb 29 SEP 1.07 2.86 SEP 0.47 2.86 SEP SEP 8 SEP 80 SEP 2.5 tb 30 SEP 1.00 2.51 SEP 0.42 2.51 SEP SEP 6 SEP 80 SEP 3 tb 31 SEP 2.00 4.9 SEP 0.81 4.9 SEP SEP 10 SEP 80 SEP 24 tb 32 SEP 1.67 4.0 SEP 0.66 4.0 SEP SEP 10 SEP 70 SEP 48 tb 33 SEP 1.22 3.0 SEP 0.50 3.0 SEP SEP 10 SEP 70 SEP 48 tb EMI28.1 Table 4 No. 1 EMI28.2 SEP Elementary SEP Analysis SEP tb SEP o SEP Solvent SEP Molecular tb Example SEP Appear SEP for SEP m.p. SEP C SEP Formula SEP Calcd. SEP Found tb No. SEP ance SEP Recrystallizat SEP ion SEP C SEP H SEP N SEP O SEP H SEP N tb 2a SEP YP SEP ethanol SEP 167 SEP SEP 173 SEP C23H29ClN4O5 SEP 57.92 SEP 6.13 SEP 11.75 SEP 57.84 SEP 6.18 SEP 11.65 tb 3 SEP YP SEP ethanol SEP 200 SEP SEP 202 SEP C24H30N4O5 SEP 63.42 SEP 6.65 SEP 12.33 SEP 63.26 SEP 6.41 SEP 12.36 tb 4 SEP YP SEP i propyl SEP ether SEP 148 SEP SEP 149 SEP C24H30N4O5 SEP 63.42 SEP 6.65 SEP 12.33 SEP 63.37 SEP 6.57 SEP 12.39 tb 5 SEP YP SEP i propyl SEP ether SEP 101 SEP SEP 103 SEP C26H30N4O5 SEP 64.71 SEP 7.10 SEP 11.61 SEP 64.89 SEP 7.07 SEP 11.53 tb 6a SEP YP SEP acetone SEP 119 SEP SEP 121a SEP C27H35ClN4O5 H2O SEP 59.06 SEP 6.79 SEP 10.20 SEP 59.15 SEP 6.55 SEP 10.08 tb 7a SEP YP SEP acetone ether SEP 115 SEP SEP 118a SEP C28H37ClN4O5 SEP 61.70 SEP 6.84 SEP 10.28 SEP 61.61 SEP 6.85 SEP 10.01 tb 8 SEP YP SEP i propanol SEP 153 SEP SEP 154 SEP C25H30N4O5 SEP 64.36 SEP 6.48 SEP 12.01 SEP 64.25 SEP 6.47 SEP 11.90 tb 9b SEP YP SEP methylene SEP 171 SEP SEP 173b SEP C30H32N4O9 H2O SEP 59.01 SEP 5.61 SEP 9.18 SEP 58.59 SEP 5.20 SEP 8.74 tb 10a SEP P SEP acetone SEP 145 SEP SEP 150a SEP C28H31ClN4O5 SEP 62.39 SEP 5.80 SEP 10.39 SEP 62.17 SEP 5.81 SEP 10.33 tb 11a SEP YP SEP acetone SEP 125 SEP SEP 130a SEP C29H35ClN4O5 H2O SEP 61.00 SEP 6.18 SEP 9.81 SEP 60.59 SEP 5.99 SEP 9.66 tb 12 SEP YP SEP i propyl SEP ether SEP 124 SEP SEP 126b SEP C25H30N4O85 1 2H2O SEP 54.04 SEP 5.62 SEP 10.08 SEP 54.28 SEP 5.36 SEP 10.05 tb 13b SEP YP SEP acetone SEP 134 SEP SEP 136b SEP C27H35N5 2H2O SEP 54.63 SEP 6.62 SEP 11.80 SEP 54.73 SEP 6.21 SEP 11.87 tb Table 4 No. 2 continued from No. 1 EMI29.1 SEP Elementary SEP Analysis SEP tb SEP o SEP Solvent SEP Molecular tb Example SEP Appear SEP for SEP m.p. SEP C SEP Formula SEP Calcd. SEP Found tb No. SEP ance SEP Recrystallizat SEP ion SEP C SEP H SEP N SEP O SEP H SEP N tb 14 SEP YA SEP SEP SEP C33H37N5O8 tb 15b SEP YP SEP methanol SEP 180 SEP SEP 182b SEP C34H39N5O8 1 2H2O SEP 62.37 SEP 6.16 SEP 10.70 SEP 62.23 SEP 6.15 SEP 10.71 tb 16a SEP YP SEP ethyl SEP acetate SEP 110 SEP SEP 113a SEP C24H33ClN4O4 SEP 60.44 SEP 6.97 SEP 11.75 SEP 60.01 SEP 6.97 SEP 11.45 tb 17b SEP YN SEP acetone SEP 180 SEP SEP 182b SEP C30H32N4O8 H2O SEP 60.60 SEP 5.76 SEP 9.42 SEP 60.60 SEP 5.44 SEP 9.33 tb 18a SEP YP SEP acetone SEP 166 SEP SEP 170a SEP C28H30Cl2N4O4 SEP 60.33 SEP 5.42 SEP 10.05 SEP 60.10 SEP 5.52 SEP 9.85 tb 19a SEP YP SEP acetone SEP 128 SEP SEP 130a SEP C30H35ClN4O6 1 2H2O SEP 60.86 SEP 6.13 SEP 9.46 SEP 61.02 SEP 6.20 SEP 9.12 tb 20 SEP YA SEP SEP SEP C29H32N4O5 SEP 67.42 SEP 6.24 SEP 10.85 tb 21 SEP P1 SEP acetone SEP 164 SEP SEP 170a SEP C30H41Cl2N4O4 SEP 64.68 SEP 7.42 SEP 10.06 SEP 64.61 SEP 7.41 SEP 9.98 tb 22a SEP YN SEP acetone SEP 125 SEP SEP 127a SEP C28H31Cl2N4O4 SEP 60.58 SEP 5.63 SEP 10.09 SEP 60.60 SEP 5.91 SEP 9.63 tb 23a SEP YP SEP acetone SEP 152 SEP SEP 155a SEP C25H33Cl2N4O4S SEP 57.63 SEP 6.38 SEP 10.75 SEP 57.43 SEP 6.43 SEP 10.63 tb 24a SEP YP SEP acetone SEP 148 SEP SEP 150a SEP C27H35Cl2N4O4S SEP 59.28 SEP 6.45 SEP 10.24 SEP 59.30 SEP 6.66 SEP 10.21 tb 25a SEP YP SEP acetone SEP 145 SEP SEP 150a SEP C27H35Cl2N4O4 SEP 62.97 SEP 6.85 SEP 10.88 SEP 62.64 SEP 6.97 SEP 10.80 tb 26a SEP YP SEP ethanol SEP 179 SEP SEP 184a SEP C27H35Cl2N4O4 SEP 62.96 SEP 6.85 SEP 10.88 SEP 62.78 SEP 9.81 SEP 10.73 tb 27a SEP YP SEP acetone SEP 141 SEP SEP 150a SEP C25H31Cl2N4O4 SEP 61.66 SEP 6.42 SEP 11.50 SEP 61.21 SEP 6.31 SEP 11.30 tb 28a SEP YP SEP acetone SEP 150 SEP SEP 155a SEP C26H33Cl2N4O4 SEP 62.33 SEP 6.64 SEP 11.18 SEP 62.10 SEP 6.46 SEP 11.25 tb a Hydrochloride, b Oxalate c YP Yellow YN Yellow YA Yellow P Colorless P1 Colorless prism Needless Amorphous Prisma Plates Table 4 No. 3 EMI30.1 SEP Elementary SEP Analysis SEP tb SEP o SEP Solvent SEP Molecular tb Example SEP Appear SEP for SEP m.p. SEP C SEP Formula SEP Calcd. SEP Found tb No. SEP ance SEP Recrystallizat SEP ion SEP C SEP H SEP N SEP O SEP H SEP N tb 29a SEP YP SEP SEP 137 SEP SEP 140a SEP C28H30ClN4O4 SEP 60.32 SEP 5.42 SEP 10.05 SEP 60.20 SEP 5.65 SEP 9.68 tb 30a SEP YP SEP ethanol SEP 150 SEP SEP 152a SEP C30H35ClN4O6 SEP 61.80 SEP 6.05 SEP 9.61 SEP 61.77 SEP 5.95 SEP 9.54 tb 31a SEP YN SEP SEP 124 SEP SEP 126a SEP C28H29ClN4O4 SEP 1 3H2O SEP 56.23 SEP 5.02 SEP 9.36 SEP 56.66 SEP 5.42 SEP 8.90 tb 32a SEP YP SEP SEP 197 SEP SEP 200a SEP C28H30BrClN4O4 SEP 55.82 SEP 4.98 SEP 9.30 SEP 55.62 SEP 4.90 SEP 9.30 tb 33a SEP CP SEP SEP 147 SEP SEP 149a SEP C29H30ClF3N4O4 SEP 58.88 SEP 5.07 SEP 9.47 SEP 58.78 SEP 4.96 SEP 9.40 tb a Hydrochloride, b Oxalate c YP Yellow YN Yellow YA Yellow P Colorless P1 Colorless prism Needless Amorphous Prisma Plates Table 5 No. 1 EMI31.1 SEP IR SEP maxcm 1 SEP NMR SEP ppmCDCl3 tb Example tb No. SEP NH SEP CO SEP NO2 tb 2 SEP 3440 SEP 1690 SEP 1350 SEP 1.25 1.92 8H,m , SEP 2.38, SEP 3.32, SEP 3.63 3H SEP x SEP 3,s , SEP 2.58 1H,m , SEP 3.51 2H,m , SEP 4.14 2H,m , tb SEP 5.25 1H,s , SEP 7.13 8.08 5H,m tb 3 SEP 3270 SEP 1695 SEP 1360 SEP 0.77 2.32 10H,m , SEP 2.35, SEP 3.28, SEP 3.65 3H SEP x SEP 3, SEP s , SEP 2.50 1H,m , SEP 3.50 2H,m , SEP 4.13 2H,m , tb SEP 5.95 1H,s , SEP 7.00 1H,br,s , SEP 7.13 7.80 4H,m tb 4 SEP 3270 SEP 1698 SEP 1378 SEP 0.83 1.77 9H,m , SEP 2.72 2.48 2H,m , SEP 2.38, SEP 3.30, SEP 3.67 3H SEP x SEP 3,s , SEP 3.45 2H,t , tb SEP 4.10 2H,t , SEP 5.90 1H,s , SEP 6.25 1H,br,s , SEP 7.07 7.77 4H,m tb 5 SEP 3240 SEP 1692 SEP 1355 SEP 0.95 2.03 10H,m , SEP 1.06 6H,d , SEP 2.37, SEP 3.67 3H SEP x SEP 2,s , SEP 2.89 1H,m , SEP 3.33 3H,m , tb SEP 4.04 2H,t , SEP 5.90 1H,s , SEP 6.68 1H,br,s , SEP 7.10 7.77 4H,m tb 6 SEP 3430 SEP 1690 SEP 1355 SEP 1.01 2.13 16H,m , SEP 2.36, SEP 3.66 3H SEP x SEP 2,s , SEP 2.58 3.20 1H,m , SEP 3.28 4.33 3H,m , tb SEP 5.91 1H,s , SEP 6.26 1H,br,s , SEP 7.03 7.77 4H,m tb 7 SEP 2570 SEP 1685 SEP 1365a SEP 1.01 3.37 20H,m , SEP 2.33, SEP 3.65 3H SEP x SEP 2,s , SEP 3.50 2H,t , SEP 3.80 4.33 2H,m , SEP 5.92 1H,s , tb SEP 2690 SEP 6.90 1H,br,s , SEP 7.07 7.73 4H,m tb 8 SEP 3250 SEP 1688 SEP 1360 SEP 0.93 2.17 12H,m , SEP 2.33, SEP 3.68 3H SEP x SEP 2,s , SEP 2.67 3.13 1H,m , SEP 3.47 4.27 5H,m , tb SEP 5.93 1H,s , SEP 7.00 7.87 5H,m tb 9 SEP 2300 SEP 1730 SEP 1378b SEP 1.05 1.93 8H,m , SEP 2.33, SEP 3.63 3H SEP x SEP 2,s , SEP 2.63 3.12 1H,m , SEP 3.77 4.47 4H,m , tb SEP 1700 SEP 5.95 1H,s , SEP 6.70 7.78 4H,m tb Table 5 No. 2 EMI32.1 SEP IR SEP maxcm 1 SEP NMR SEP ppmCDCl3 tb Example tb No. SEP NH SEP CO SEP NO2 tb 10 SEP 2530 SEP 1700 SEP 1360a SEP 1.22 2.80 9H,m , SEP 2.42, SEP 3.67 3H SEP x SEP 2,s , SEP 4.07, SEP 4.37 2H SEP x SEP 2,m , SEP 5.27 1H,s , tb SEP 7.05 1H,br,s , SEP 7.05 8.08 9H,m tb 11 SEP 2530 SEP 1679 SEP 1357a SEP 0.83 2.77 11H,m , SEP 2.35, SEP 3.63 3H SEP x SEP 2,s , SEP 3.92 4.08 2H,m , SEP 4.17 4.50 2H,m , tb SEP 2650 SEP 3.91 1H,s , SEP 6.90 1H,br,s , SEP 6.75 7.70 9H,m tb 12 SEP 2300 SEP 1702 SEP 1378b SEP 1.00 3.20 1H,m , SEP 2.07, SEP 2.35, SEP 3 65 3H SEP x SEP 3,s , SEP 3.83 4.33 2H,m , SEP 5.90 1H,s , tb SEP 7.00 8.03 4H,m tb 13 SEP 3430 SEP 1690 SEP 1355 SEP 1.10 2.58 11H,m , SEP 2.22 6H,s , SEP 2.38, SEP 3.70 3H SEP x SEP 2,s , SEP 2.72 3.83 2H,m , tb SEP 3.57 4.30 2H,m , SEP 5.91 1H,s , SEP 6.95 7.81 4H,m tb 14 SEP 3430 SEP 1685 SEP 1350 SEP 1.08 3.03 15H,m , SEP 2.30, SEP 3.58 3H SEP x SEP 2,s , SEP 3.50 2H,s , SEP 4.87 5.20 1H,m , SEP 6.02 1H,s , tb SEP 7.01 7.85 10H,m tb 15 SEP 3430 SEP 1680 SEP 1350 SEP 1.12 3.00 17H,m , SEP 2.32, SEP 3.63 3H SEP x SEP 2,s , SEP 4.43 4.90 1H,m , SEP 6.21 1H,s , tb SEP 7.10 7.86 9H,m tb 16 SEP 2570 SEP 1697 SEP 1357a SEP 0.77 3.16 18H,m , SEP 2.34, SEP 3.63 3H SEP x SEP 2,s , SEP 3.75 4.07 2H,m , SEP 5.92 1H,s , SEP 6.98 tb SEP 2675 SEP 1H,br,s , SEP 7.07 7.73 4H,m tb 17 SEP 2300 SEP 1733 SEP 1375b SEP 1.10 2.00 8H,m , SEP 2.27, SEP 3.62 3H SEP x SEP 2,s , SEP 2.57 3.27 3H,m , SEP 3.87 4.50 2H,m , tb SEP 1700 SEP 5.93 1H,s , SEP 7.00 8.27 9H,m tb Table 5 No.3 EMI33.1 SEP IR SEP maxcm 1 SEP NMR SEP ppmCDCl3 tb Example tb No. SEP NH SEP CO SEP NO2 tb 18 SEP 2370 SEP 1705 SEP 1360a SEP 1.10 3.20 9H,m , SEP 2.29, SEP 3.67 3H SEP x SEP 3,s , SEP 2.73 2H,t , SEP 3.90 4.37 2H,m , SEP 5.88 1H,s , tb SEP 6.74 1H,br,s , SEP 6.99 7.73 8H,m tb 19 SEP 2360 SEP 1699 SEP 1348a SEP 1.11 3.18 9H,m , SEP 3.30, SEP 3.64 3H SEP x SEP 2,s , SEP 2.70 2H,t , SEP 3.82 6H,s , SEP 3.93 4.29 2H,m , tb SEP 5.90 1H,s , SEP 6.72 3H,s , SEP 6.83 1H,br,s , SEP 7.07 7.73 4H,m tb 20 SEP 3430 SEP 1690 SEP 1350 SEP 1.10 2.77 9H,m , SEP 2.37, SEP 3.20, SEP 3.24, SEP 3.66 3H SEP x SEP 4,s , SEP 3.97 4.50 3H,m , SEP 5.22 1H,s tb SEP 6.92 1H,br,s , SEP 7.12 8.08 9H,m tb 21 SEP 3425 SEP 1675 SEP 1340 SEP 0.37 2.70 27H,m , SEP 4.67 1H,m , SEP 2.38, SEP 2.45, SEP 3.66 3H SEP x SEP 3,s , SEP 5.20, SEP 5.27 1H,2s , SEP 6.80, tb SEP 6.93 1H,2 SEP br,s , SEP 7.20 8.12 4H,m . tb 22 SEP 2700 SEP 1694 SEP 1352a SEP 1.0 1.93 8H,m , SEP 2.3 3H,s , SEP 2.67 3.23 3H,m , SEP 3.6 3H,s , SEP 3.85 4.33 2H,m , SEP 5.85 1H,s tb SEP 6.87 8.03 9H,m tb 23 SEP 2670 SEP 1705 SEP 1363a SEP 1.0 3.20 9H,m , SEP 1.23 3H SEP x SEP 2,d , SEP 2.37, SEP 3.67 3H SEP x SEP 2,s , SEP 2.56 2H,t , SEP 2.93 3H,sep , tb SEP 3.83 4.30 2H,m , SEP 5.90 1H,s , SEP 7.0 1H,br,s , SEP 7.12 7.77 4H,m tb 24 SEP 2480 SEP 1701 SEP 1359a SEP 1.03 3.30 18H,m , SEP 2.38, SEP 3.68 3H SEP x SEP 2,s , SEP 2.58 2H,t , SEP 3.87 4.33 2H,m , SEP 5.91 1H,s , tb SEP 6.88 1H,br,s , SEP 7.13 7.77 4H,m tb 25 SEP 2320 SEP 1700 SEP 1358a SEP 0.77 3.10 20H,m , SEP 2.33, SEP 3.62 3H SEP x SEP 2,s , SEP 3.73 4.17 2H,m , SEP 5.90 1h,s , SEP 6.83 tb SEP 1H,br,s , SEP 7.07 7.73 4H,m tb Tanble 5 No. 4 EMI34.1 SEP IR SEP maxcm 1 SEP NMR SEP ppmCDCl3 tb Example tb No. SEP NH SEP CO SEP NO2 tb 26 SEP 2450 SEP 1701 SEP 1355a SEP 0.53 2.30 19H,m , SEP 2.38 3H,s , SEP 2.71 3.20 1H,m , SEP 3.50 4.28 2H,m , SEP 3.68 3H,s , tb SEP 5.94 1H,s , SEP 6.52 1H,br,s , SEP 7.10 0.81 4H,m tb 27 SEP 2530 SEP 1683 SEP 1358 SEP 1.03 3.17 17H,m , SEP 2.32, SEP 3.62 3H SEP x SEP 2,s , SEP 5.03 1H,m , SEP 6.03 1H,s , SEP 6.90 1H,br,s , tb SEP 7.10 7.82 4H,m tb 28 SEP 2525 SEP 1702 SEP 1355a SEP 0.9 3.13 19H,m , SEP 2.36, SEP 3.63 3H SEP x SEP 2,s , SEP 4.62 1H,m , SEP 6.03 1H,s , SEP 6.82 1H,br,s , tb SEP 7.10 7.84 4H,m tb a Hydrochloride, b Oxalate o Data of NMR are shown as those on free bases. Table 5 No. 5 EMI35.1 Example SEP IR SEP gamma maxcm 1 SEP NMR ppmCDCl3 tb SEP No. SEP NH SEP CO SEP NO2 tb SEP 3420 SEP 1.15 2.0 8H,m , SEP 2.35 3H,m , SEP 2.60 1H,m , SEP 2.70 2.93 2H,m , SEP 3.66 3H,s , SEP 4.04 4.37 tb SEP 29 SEP 3270 SEP 1685 SEP 1350 SEP 2H,m , SEP 5.12 1H,s , SEP 6.35 1H,s , SEP 6.99 8.01 8H,m tb SEP 3420 SEP 1.15 1.72 8H,m , SEP 2.36 3H,s , SEP 2.58 1H,m , SEP 2.83 2H,m , SEP 3.67 3H,s , SEP 3.85 6H,s , tb SEP 30 SEP 3280 SEP 1685 SEP 1350 SEP 4.24 2H,m , SEP 5.20 1H,s , SEP 6.65 8.05 8H,m tb SEP 31 SEP 2670 SEP 1700 SEP 1375a SEP 1.07 3.32 9H,m , SEP 2.30 3H,s , SEP 2.75 2H,t , SEP 3.67 3H,a , SEP 4.17 2H,t , SEP 5.90 1H,s , tb SEP 6.83 7.80 4H,m , SEP 8.27 1H,s tb SEP 32 SEP 2380 SEP 1713 SEP 1355a SEP 1.07 2.0 8H,m , SEP 2.27 3H,s , SEP 2.72 2H,t , SEP 2.72 3.18 1H,m , SEP 3.62 3H,s , SEP 5.87 1H,s , tb SEP 6.83 7.83 8H,m tb SEP 33 SEP 2680 SEP 1715 SEP 1338a SEP 1.07 2.13 8H,m , SEP 2.25 3H,s , SEP 2.55 3.20 1H,m , SEP 2.83 2H,t , SEP 3.62 3H,s , SEP 4.17 2H,t , tb SEP 5.87 1H,s , SEP 6.97 7.83 8H,m tb EXAMPLE 34 Components for tablet Phenethyl 3 cyclopentyl 1,6 dimethyl 4 2 nitrophenyl 4, 7 dihydropyrazolo 3,4 b pyridine 5 carboxylate 10 mg Corn starch 50 mg Gelatis 7.5 mg Avicel 25 Mg Magnesium stearate 2.5 mg Total 95 mg These substances are formulated into a tablet. PREPARATION 1Preparation of 2 methoxyethyl 2 nitrobenzylideneacetoacetate 6EMI36.1 A solution of 4.80 g 30.0 mMol of methoxyethylacetoacetate 5, 4.53 g 30.0 mMol of 2 nitrobenzaldehyde 4, 1.0 al of acetic acid and 0.3 ml of piperidine in 25 ml of benzene is stirred at room temperature for 17 hours, and the mixture is ref fluxed for 2 hours in a condition of azeotropic distillation. The reaction mixture is washed with water, dried over magnesium sulfate, filtered, and evaporated. The residue is chromatographed on silica gel for purification to give 7.93 g 90.2X yield of the titled compound 6 as an yellow oil from the eluate with dichloromethane ethyl acetate 95 5 . NMR CDC13 Gppm 2.23, 2.48 3H, 2s , 3.17 3.80 2H, m , 3.22, 3.40 3H, 2s , 4.08 4.53 2H, m , 7.33 8.33 5H, m . PREPARATIONs 2 30EMI37.1 wherein R1 has the same meaning as defined above. A solution of the compound ME and a compound M in a solvent is allowed to react in the presence of an organic base at room temperature or under heating, and then ref fluxed if needed. The reaction fixture is washed with water, dried, filtered, and evaporated. According to the requisition, the resulting residue is subjected to recrystallization or chromatography on silica gel in order to purify. Each of the compounds I listed in the followingTable 6 can be prepared in the above depicted manner The yield for a compound I is listed in Table 6. The Process for production of the starting substances IX is depicted over the top of Table 6, the yield of which is also listed inTable 6. In addition, the detailes of the reaction conditions for the above reaction Preparations 2 25 are summarized i Table 7. Data of pelting point and NMR spectrum on each of the compounds I and the starting substances IX are summarized in Table 8. EMI39.1 Table 6 No.1. VIII EMI39.2 tb repn. SEP Yield SEP of SEP Position SEP Yield SEP of SEP I tb SEP repn. SEP RZ SEP X SEP SEP of SEP ff SEP SEP SEP tb SEP N02 tb SEP 2 SEP CH2CH20CH3 SEP Compd. SEP 3 SEP 88.4 tb SEP marketed tb SEP 3 SEP CH2CH2CH20CIf3 SEP 72 7 SEP 2 SEP 50 7 tb SEP 3 tb SEP 4 SEP CBZCRZO a SEP 68.1 SEP n SEP 84.0 tb SEP l tb SEP 5 SEP g SEP CH2CH20 0 SEP zo SEP 94.1 SEP . SEP 91.6 tb SEP I tb SEP 6 SEP CH21 SEP 74.6 SEP n SEP 794 tb SEP 7 SEP C2CHiO SEP 865 SEP n SEP 94.4 tb SEP g SEP CH2CH2SCH3 SEP 25.1 SEP 2 SEP 86.7 tb SEP 10 SEP SEP CE2CE2CK2NEE3 SEP 79.0 SEP 53.1 tb SEP 3 tb SEP 11 SEP zoN CH2 SEP 4 SEP 95.0 SEP n SEP 84.6 tb SEP 12 SEP 4 SEP CH2 SEP 4 SEP 81.0 SEP n SEP 62.2 tb SEP u tb SEP 13 SEP 1 SEP Cz2 4Cz3 SEP 77.0 SEP a9.O tb SEP 14 SEP CH2CH2 SEP 89.3 SEP n SEP n SEP 1 SEP 88.2 tb SEP 15 SEP CH2CH2 C1 SEP 958 SEP SEP 93.8 tb SEP SEP 1.0 tb Table 6 No.2 EMI40.1 Propn SEP R SEP Yield SEP of SEP Position SEP Yield SEP of tb SEP No. SEP IX SEP SEP of SEP II SEP tb SEP NO2 tb SEP 16 SEP CH2CH2 OCH3 SEP SEP 92.9 SEP 2 SEP 96.8 tb SEP OCH3 tb SEP 17 SEP CHCH2 SEP SEP 89.6 SEP 3 SEP 87.5 tb SEP 18 SEP CH3 SEP SEP 89.4 SEP 3 SEP 71.2 tb SEP 19 SEP CH2CH2S SEP 99.6 SEP 2 SEP 84.2 tb SEP CH3 tb SEP 20 SEP CH2CH2S CH SEP 96.6 SEP SEP 93.2 tb SEP CH3 tb SEP 21 SEP CH2CH2 S SEP 92.1 SEP SEP 92.4 tb SEP 22 SEP CH2CH2 SEP SEP 96.6 SEP SEP 97.4 tb 23 SEP CH2 SEP SEP 94.5 SEP SEP 85.5 tb SEP 24 SEP SEP SEP 92.9 SEP SEP 97.7 tb SEP 25 SEP SEP SEP 93.5 SEP SEP 97.3 tb Disclosed in IX 18 F.Korts, F.Yuesten, Liebigs Ann., 647, 18 1961 Material for IX IIEMI40.2 Disclosed in E.Jaeger, J.H.Biel, J.Org.Chem. 30, 740 1965 Ph Phenyl Table 6 No.3 EMI41.1 Prepn. SEP RÚ SEP Yield SEP of SEP Position SEP Yield SEP of tb SEP No. SEP IX SEP SEP of SEP II SEP tb SEP NO2 tb SEP 26 SEP Cl SEP vide SEP supra SEP 3 SEP 98.0 tb SEP 27 SEP OMe SEP vide SEP supra SEP 3 SEP 90.4 tb SEP OMe tb SEP 28 SEP Cl SEP 90.6 SEP 2 SEP 93.1 tb SEP Cl tb SEP 29 SEP Br SEP 98.1 SEP 2 SEP 76.5 tb SEP 30 SEP SEP 97.2 SEP 2 SEP 54.1 tb SEP CF3 tb EMI42.1 EMI42.2 Prepn. SEP Amoundt SEP used SEP g SEP mmol. SEP Solvent SEP Reation SEP Reaction tb SEP No. SEP Compd. VII SEP Compd. IX SEP ml SEP Temp. SEP Time tb SEP C SEP hrs. tb SEP 2 SEP 4.53 30.0 SEP 4.80 30.0 SEP benzene SEP 25 SEP r.t. SEP 21 tb SEP F 0.1 , SEP AcOH 0.3 tb 3 SEP 2.04 13.5 SEP 2.72 13.4 SEP benzene SEP 5 SEP r.t. SEP 100 tb SEP F 0.1 , SEP AcOH 0.2 SEP reflux SEP 1 tb SEP 4 SEP 0.30 1.96 SEP 0.42 1.96 SEP benzene SEP 2 SEP r.t. SEP 72 tb SEP F 0.004 , SEP AcOH 0.01 SEP reflux SEP 2 tb SEP 5 SEP 1.51 10.0 SEP 2.28 10.0 SEP benzene SEP 5 SEP r.t. SEP 72 tb SEP F 0.05 , SEP AcOH 0.2 SEP reflux SEP 3 tb SEP 6 SEP 4.53 30.0 SEP 5.58 30.0 SEP benzene SEP 10 SEP r.t. SEP 72 tb SEP F 0.1 , SEP AcOH 0.4 tb SEP 7 SEP 4.76 31.5 SEP 7.0 31.5 SEP benzene SEP 10 SEP 40 SEP 100 tb SEP F 0.05 , SEP AcOH 0.2 SEP reflux SEP 2 tb SEP 8 SEP SEP SEP SEP SEP tb SEP 9 SEP 3.78 25.0 SEP 4.4 25.0 SEP benzene SEP 5 SEP r.t. SEP 72 tb SEP F 0.1 , SEP AcOH 0.4 tb SEP 10 SEP 4.53 30.0 SEP 5.62 30.0 SEP benzene SEP 10 SEP r.t. SEP 72 tb SEP F 0.1 , SEP AcOH 0.4 tb SEP 11 SEP 0.91 6.01 SEP 1.57 6.01 SEP benzene SEP 3 SEP r.t. SEP 48 tb SEP F 0.01 , SEP AcOH 0.04 SEP reflux SEP 1 tb SEP 12 SEP 1.14 7.57 SEP 2.08 7.57 SEP benzene SEP 4 SEP reflux SEP 4 tb F 0.01 , SEP AcOH 0.04 tb SEP 13 SEP 6.14 40.6 SEP 7.00 40.6 SEP benzene SEP 10 SEP 40 SEP 100 tb SEP F 0.05 , SEP AcOH 0.2 SEP reflux SEP 2 tb 14 SEP 4.53 30.0 SEP 6.18 30.0 SEP benzene SEP 10 SEP r.t. SEP 72 tb SEP F 0.1 , SEP AcOH 0.4 SEP reflux SEP 3 tb Table 7 No.2 EMI43.1 Prepn. SEP Amoundt SEP used SEP g SEP mmol. SEP Solvent SEP Reation SEP Reaction tb SEP No. SEP Compd. VII SEP Compd. IX SEP ml SEP Temp. SEP Time tb SEP C SEP hrs. tb SEP 15 SEP 1.51 10.0 SEP 2.41 10.0 SEP benzene SEP 5 SEP r.t. SEP 72 tb SEP P 0.05 , SEP AcOH 0.2 SEP reflux SEP 2 tb SEP 16 SEP 1.51 10.0 SEP 2.66 10.0 SEP benzene SEP 5 SEP r.t. SEP 72 tb SEP P 0.05 , SEP AcOH 0.2 SEP reflux SEP 3 tb SEP 17 SEP 1.62 10.7 SEP 2.53 10.7 SEP benzene SEP 2 SEP r.t. SEP 72 tb SEP P 0.02 , SEP AcOH 0.1 SEP reflux SEP 7 tb SEP 18 SEP 4.0 26.5 SEP 6.38 26.5 SEP benzene SEP 10 SEP r.t. SEP 72 tb SEP P 0.05 , SEP AcOH 0.2 SEP reflux SEP 7 tb SEP 19 SEP 3.0 20.0 SEP 4.76 20.0 SEP benzene SEP 20 SEP r.t. SEP 16 tb SEP P 0.1 , SEP AcOH 0.2 SEP reflux SEP 2 tb SEP 20 SEP 4.89 32.3 SEP 6.6 32.3 SEP benzene SEP 20 SEP r.t. SEP 16 tb SEP P 0.15 , SEP AcOH 0.3 SEP reflux SEP 1 tb SEP 21 SEP 4.34 29.1 SEP 6.7 29.1 SEP benzene SEP 20 SEP r.t. SEP 16 tb SEP P 0.15 , SEP AcOH 0.3 SEP reflux SEP 1 tb SEP 22 SEP 3.58 23.7 SEP 4.7 23.7 SEP benzene SEP 20 SEP r.t. SEP 16 tb SEP P 0.3 , SEP AcOH 0.6 SEP reflux SEP 1 tb SEP 23 SEP 4.53 30.0 SEP 5.95 30.0 SEP benzene SEP 10 SEP r.t. SEP 16 tb SEP P 0.3 , SEP AcOH 0.6 SEP reflux SEP 1 tb SEP 24 SEP 2.66 17.6 SEP 3.0 17.6 SEP benzene SEP 6 SEP r.t. SEP 16 tb SEP P 0.05 , SEP AcOH 0.2 SEP reflux SEP 2 tb SEP 25 SEP 2.46 16.3 SEP 3.0 16.3 SEP benzene SEP 6 SEP r.t. SEP 16 tb SEP P 0.05 , SEP AcOH 0.2 SEP reflux SEP 2 tb Table 7 No.3 EMI44.1 Prepn. SEP Amount SEP used SEP g mmol. SEP Solvent SEP Reaction SEP Reaction tb SEP No. SEP Compd. SEP Compd. SEP ml SEP Temp. SEP Time tb SEP VIII SEP IX SEP C SEP hrs. tb SEP 26 SEP 2.78 18.38 SEP 4.42 18.37 SEP benzene SEP 9 SEP r.t. SEP 96 tb SEP P 0.036 , SEP AcOH 0.1 SEP reflux SEP 2 tb SEP 27 SEP 1.0 6.64 SEP 1.77 6.64 SEP benzene SEP 4 SEP r.t. SEP 96 tb SEP P 0.013 , SEP AcOH 0.038 SEP reflux SEP 2 tb SEP 28 SEP 1.51 10.0 SEP 2.75 10.0 SEP benzene SEP 10 SEP r.t. SEP 20 tb SEP P 0.1 , SEP AcOH 1.0 SEP reflux SEP 2 tb SEP 29 SEP 1.51 10.0 SEP 2.85 10.0 SEP benzene SEP 10 SEP r.t. SEP 20 tb SEP P 0.1 , SEP AcOH 1.0 SEP reflux SEP 2 tb SEP 30 SEP 1.51 10.0 SEP 2.74 10.0 SEP benzene SEP 10 SEP r.t. SEP 20 tb SEP P 0.1 , SEP AcOH 1.0 SEP reflux SEP 2 tb P Piperidine, AcOH Acetic acid, r.t. room temperature Table 8 No.1 CH3COCH2COORÚ IX EMI45.1 Prepn. SEP Boiling SEP point SEP NMR SEP ppmCDCl3 tb SEP No. SEP C SEP mmHg tb IX 3 SEP 90 91 SEP 0.6 SEP 1.12 6H,d , SEP 1.93 2H,m , SEP 2.55 3H,s , SEP 3.33 4.02 3H,m , SEP 3.45 2H,s , SEP 4.23 2H,t tb SEP 4 SEP 96 100 SEP 0,1 SEP 1.15 1.90 8H,m , SEP 2.27 3H,s , SEP 3.36 4.47 5H,m , SEP 3.47 2H,s tb SEP 5 SEP 118 120 SEP 0.4 SEP 1.15 2.07 10H,m . SEP 2.26 3H,s , SEP 3.25 1H,m , SEP 3.45 2H,s , SEP 3.63, SEP 4.26 2H SEP x SEP 2,s tb SEP 6 SEP 95 100 SEP 0.9 SEP 1.33 2.17 4H,m , SEP 2.27 3H,s , SEP 3.50 2H,s , SEP 3.53 4.33 4H,m tb SEP 7,8 SEP 140 143 SEP 0.7 SEP 2.20 3H,s , SEP 3.43 2H,s , SEP 4.03 4.60 4H,m , SEP 6.73 7.43 5H,m tb SEP 9 SEP 160 162 SEP 25 SEP 2.13, SEP 2.27 3H SEP x SEP 2,s , SEP 2.72 2H,t , SEP 3.45 2H,s , SEP 4.28 2H,t tb SEP 10 SEP 138 141 SEP 23 SEP 1.40 2.98 4H,m , SEP 2.20 6H,s , SEP 2.23 3H,s , SEP 3.45 2H,s , SEP 4.18 2H,t tb SEP 11 SEP oil SEP 1.63 2.98 6H,m , SEP 2.23 3H,s , SEP 3.42, SEP 3.63 2H SEP x SEP 2,s , SEP 5.24 1H,m , SEP 7.31 5H,s tb SEP 12 SEP oil SEP 1.48 2.82 8H,m , SEP 2.23 3H,s , SEP 3.40, SEP 3.47 2H SEP x SEP 2,s , SEP 4.83 1H,m , SEP 7.27 5H,s tb Table 8 No.2 EMI46.1 Prepn. SEP Boiling SEP point SEP NMR SEP ppmCDCl3 tb SEP No. SEP C SEP mmHg tb IX 13 SEP 105 111 SEP 8 SEP 0.67 2.17 9H,m , SEP 2.27 3H,s , SEP 3.45 2H,s , SEP 4.13 2H,t tb SEP 14 SEP 110 115 SEP 0.8 SEP 2.15 3H,s , SEP 2.93 2H,t , SEP 3.38 2H,s , SEP 4.33 2H,t , SEP 7.23 5H,s tb SEP 15 SEP 155 158 SEP 0.7 SEP 1.18 3H,s , SEP 2.90 2H,t , SEP 3.39 2H,s , SEP 4.30 2H,t , SEP 7.10, SEP 7.26 2H SEP x SEP 2,d tb SEP 16 SEP 182 185 SEP 0.8 SEP 2.19, SEP 3.82, SEP 3.85 3H SEP x SEP 3,s , SEP 2.88 2H,t , SEP 3.40 2H,s , SEP 3.42 2H,t , SEP 6.75 3H,m tb SEP 17 SEP oil SEP 2.23, SEP 3.23 3H SEP x SEP 2,s , SEP 3.46 2H,s , SEP 4.37 3H,m , SEP 7.28 5H,s tb SEP 18 SEP 95 101 SEP 0.3 SEP 0.62 2.35 18H,m , SEP 4.73 1H,m , SEP 2.35 3H,s , SEP 3.42 2H,s tb SEP 19 SEP oil SEP 2.18 3H,s , SEP 3.08 2H,t , SEP 3.33 3H,s , SEP 4.20 2H,t , SEP 6.97 7.37 5H,m tb SEP 20 SEP oil SEP 1.25 3H SEP x SEP 2,d , SEP 2.27 3H,s , SEP 2.75 2H,t , SEP 3.02 1H,q , SEP 3.43 2H,s , SEP 4.23 2H,t tb SEP 21 SEP oil SEP 1.13 2.23 8H,m , SEP 2.47 3H,s , SEP 3.73 2H,t , SEP 2.93 3.27 1H,m , SEP 3.43 2H,s , SEP 4,23 2H,t tb SEP 22 SEP oil SEP 1.03 2.0 11H,m , SEP 2.23 3H,s , SEP 3.4 2H,s , SEP 4.3 2H,t tb Table 8 No.3 EMI47.1 Prepn. SEP C SEP mmHg SEP NMR SEP ppmCDCl3 tb SEP No. SEP Boiling SEP point tb IX 23 SEP oil SEP 0.67 2.03 11H,m , SEP 2.2 3H,s , SEP 3.40 2H,s , SEP 3.95 2H,d tb SEP 24 SEP 103 106 SEP 6 SEP 0.96 2.10 8H,m , SEP 2.28 3H,s , SEP 3.43 2H,s , SEP 5.25 1H,m tb SEP 25 SEP 116 119 SEP 6 SEP 0.97 2.04 10H,m , SEP 2.25 3H,s , SEP 3.42 2H,s , SEP 4.82 1H,m tb Table 8 No.4 EMI48.1 Prepn. SEP Boiling SEP point SEP NMR SEP ppmCDCl3 tb SEP No. SEP C SEP mmHg tb IX 26 SEP vide SEP supra SEP vide SEP supra tb SEP 27 SEP vide SEP supra SEP vide SEP supra tb SEP 28 SEP oil SEP 2.18 3H,m , SEP 2.90 2H,t , SEP 3.40 2H,s , SEP 4.30 2H,t , SEP 6.90 7.43 3H,m tb SEP 29 SEP oil SEP 2.18 3H,s , SEP 2.88 2H,t , SEP 3.40 2H,s , SEP 4.32 2H,t , SEP 6.93 7.53 4H,m tb SEP 30 SEP oil SEP 2.20 3H,s , SEP 3.02 2H,t , SEP 3.42 2H,s , SEP 4.37 2H,t , SEP 7.43 4H,s tb EMI49.1 Table 8 No.5 EMI49.2 Prepn. SEP Boiling SEP point SEP NMR SEP ppmCDCl3 tb SEP No. SEP C tb II 2 SEP mp.73 45 C SEP 2.43, SEP 6.28 3H SEP x SEP 2,s , SEP 3.50 3.75 2H,m , SEP 4.30 4.55 2H,m , SEP 7.33 8.33 5H,m tb SEP 3 SEP oil SEP 1.08 6H,d , SEP 4.52 2.07 2H,m , SEP 2.47 3H,s , SEP 3.12 4.48 5H,m , SEP 7.27 8.25 5H,m tb SEP 4 SEP oil SEP 1.07 1.84 8H,m , SEP 2.23, SEP 2.49 3H,2s , SEP 3.17 4.47 5H,m , SEP 7.36 8.31 5H,m tb SEP 5 SEP oil SEP 0.77 2.10 10H,m , SEP 2.22, SEP 2.47 3H,2s , SEP 3.17 1H,m , SEP 3.43, SEP 3.72 2H,2t , SEP 4.17, SEP 4.42 tb SEP 2H,2t , SEP 7.27 8.30 5H,m tb SEP 6 SEP oil SEP 1.03 2.17 4H,m , SEP 2.23, SEP 2.47 3H,2s , SEP 3.47 4.37 5H,m , SEP 7.23 8.36 5H,m tb SEP 7 SEP oil SEP 2.18, SEP 2.42 3H,2s , SEP 3.70 4.70 4H,m , SEP 6.60 8.23 10H,m tb SEP 8 SEP mp.127 161 C SEP 2.44 3H,s , SEP 4.18, SEP 4.65 2H SEP x SEP 2,t , SEP 6.72 8.33 10H,m tb Table 8 No.6 EMI50.1 Prepn. SEP melting SEP point SEP NMR SEP ppmCDCl3 tb SEP No. SEP C tb II SEP 9 SEP oil SEP 2.00, SEP 2.17 3H,2s , SEP 2.22, SEP 2.48 3H,2s , SEP 2.45, SEP 2.83 2H,2t , SEP 4.17, SEP 4.45 2H,2t tb SEP 7.20 8.55 5H,m tb SEP 10 SEP oil SEP 1.38 2.33 4H,m , SEP 2.13 6H,s , SEP 2.47 3H,s , SEP 4.05, SEP 4.33 2H,2t , SEP 7.25 8.33 5H,m tb SEP 11 SEP oil SEP 1.36 3.06 6H,m , SEP 2.20, SEP 2.45 3H,2s , SEP 3.50, SEP 3.65 2H,2s , SEP 4.99 5.48 1H,m , tb SEP 7.16 8.27 10H,m tb SEP 12 SEP oil SEP 1.09 2.85 8H,m , SEP 2.18, SEP 2.46 3H,2s , SEP 3.39, SEP 3.51 2H,2s , SEP 4.62 5.25 1H,m , tb SEP 7.07 8.41 10H,m tb SEP 13 SEP oil SEP 0.63 2.02 9H,m , SEP 2.20, SEP 2.47 3H,2s , SEP 3.98, SEP 4.27 2H,2t , SEP 7.35 8.27 5H,m tb SEP 14 SEP oil SEP 2.12, SEP 2.40 3H,2s , SEP 2.68, SEP 3.00 2H,2t , SEP 4.22, SEP 4.47 2H,2t , SEP 6.83 8.23 10H,m tb SEP 15 SEP oil SEP 2.10, SEP 2.43 3H,2s , SEP 2.68, SEP 3.00 2H,2t , SEP 4.20, SEP 4.48 2H,2t , SEP 6.87 8.30 9H,m tb SEP 16 SEP oil SEP 2.08, SEP 2.40 3H,2s , SEP 2.62, SEP 2.93 2H,2t , SEP 3.78, SEP 3.83, SEP 3.85 6H,3s , SEP 4.18, SEP 4.45 2H,2s tb SEP 6.43 8.30 8H,m tb Table 8 NO.7 EMI51.1 Prepn. SEP melting SEP point SEP NMR SEP ppmCDCl3 tb SEP No. SEP C tb II 17 SEP oil SEP 2.33, SEP 2.41 3H,2s , SEP 3.20, SEP 3.31 3H,2s , SEP 4.43 3H,m , SEP 7.28 8.27 10H,m tb SEP 18 SEP oil SEP 0.48 2.48 16H,m , SEP 4.90 1H,m , SEP 2.38 3H,s , SEP 7.38 8.35 5H,m tb SEP 19 SEP oil SEP 2.17, SEP 2.42 3H,s , SEP 2.82, SEP 3.18 2H,t , SEP 4.12, SEP 4.37 2H,t , SEP 7.0 8.23 10H,m , tb SEP 20 SEP oil SEP 1.2, SEP 1.32 3H SEP x SEP 2,d , SEP 2.23, SEP 2.5 3H,s , SEP 2.5, SEP 2.87 2H,t , SEP 2.77 3.17 1H,m , SEP 4.15, tb SEP 4.42 2H,t , SEP 7.23 8.33 5H,m tb SEP 21 SEP oil SEP 1.07 2.11 8H,m , SEP 2.23, SEP 2.48 3H,s , SEP 2.52, SEP 2.87 2H,t , SEP 2.73 3.33 1H,m , SEP 4.17 tb SEP 4.4 2H,t , SEP 7.27 8.37 5H,m tb SEP 22 SEP oil SEP 0.67 2.0 11H,m , SEP 2.2, SEP 2.45 3H,s , SEP 3.98, SEP 4.27 2H,t , SEP 7.23 8.3 5H,m tb SEP 23 SEP oil SEP 0.5 2.0 11H,m , SEP 2.2, SEP 2.43 3H,s , SEP 3.8, SEP 4.07 2H,d , SEP 7.27 8.33 5H,m tb SEP 24 SEP oil SEP 1.17 2.07 8H,m , SEP 2.20, SEP 2.47 3H,s , SEP 5.0 5.50 1H,m , SEP 7.30 8.29 4H,m tb SEP 25 SEP oil SEP 0.83 2.17 10H,m , SEP 2.22, SEP 2.47 3H,s , SEP 4.57 5.17 1H,m , SEP 7.30 8.28 5H,m tb Table 8 No.8 EMI52.1 Prepn. SEP melting SEP point SEP NMR SEP ppmCDCl3 tb SEP No. SEP C tb II 26 SEP oil SEP 2.25, SEP 2.37 3H,s , SEP 2.80 3.09 2H,m , SEP 4.35 4.57 2H,m , SEP 6.91 6.29 9H,m tb SEP 27 SEP oil SEP 2.27, SEP 2.38 3H,s , SEP 2.78 3.04 2H,m , SEP 3.77, SEP 3.80 3H,s , SEP 3.83, SEP 3.87 3H , SEP 4.35 4.57 2H,m tb SEP 6.59 8.28 8H,m tb SEP 28 SEP oil SEP 2.12, SEP 2.43 3H,s , SEP 2.67, SEP 2.97 2H,t , SEP 4.20, SEP 4.45 2H,t , SEP 6.72 8.27 7H,m tb SEP 29 SEP oil SEP 2.12, SEP 2.40 3H,s , SEP 2.69, SEP 2.95 2H,t , SEP 4.18, SEP 4.43 2H,t , SEP 6.73 8.27 9H,m tb SEP 30 SEP oil SEP 2.10, SEP 2.40 3H,m , SEP 2.77, SEP 3.08 2H,t , SEP 4.23, SEP 4.48 2H,t , SEP 7.10 8.27 9H,m tb PREPARATION 31 i Preparation of 3 cyclopentylcarbonylacetonitrile 9EMI53.1 To 20 ml of tetrahydrofuran is added 15.6 ml 26 mMol of butyl lithium in an atmosphere at 78µC, and 1.3 g 32 mMol of acetonitrile is dropwisely added to the mixture over the period of 40 minutes. Two hours later, 3.43 g 25.9 mMol of cyclopentylcarbonyl chloride 7 is further added dropwisely over a period of 40 minutes. The reaction mixture is, after being stirred for 2 hours, neutralized with 10 x hydrochloric acid and extracted with ether. The extract solution is dried over magnesium sulfate, filtered, and then evaporated. The resulting residue is subjected to column chromatography to give 2.91 g 80.8 yield of the titled compound 9 as an oil from the chloroform layer . NMR CDC1, Gppm 1.43 2.2 8H, m , 2.7 3.33 1H, m , 3.53 2H, s . Preparation of 5 amino 3 cyclopentyl 1 methylpyrazole IIEMI54.1 To a solution of 13.21 g 96.3 mMol of 3cyclopentylcarbonylacetonitrile 9 in 10 ml of dioxane is added 4.44 g 96.3 atfol of methyldrazine 10 under ice cooling, and the Mixture is stirred at room temperature for 17 hours.The reaction fixture is evaporated. The resulting residue is recrystallized fro. ethyl acetate hexane 5 2 to give 12.9 g 80.8 X yield of the titled compound 11 as colorless needles, mp. 149 150 CNMR CDCl3 ppm 1.33 2.20 8H,m , 2.60 3.10 1H,m , 3.57 5H, s , 5.32 iR, s . PREPARATlONS 32 and 33EMI54.2 wherein R2 and R3 have the same meanings as defined above respectively. A solution of compounds N and V in a solvent is allowed to react at room temperature, then evaporated, and the resulting residue is purified by recrystallization, if needed. In the above depicted manner, the compounds m can be prepared. Details of the reaction conditions are summarized in Table 9, and data such as yield, melting points, and NMR spectrum on the compounds are in Table 10. Table 9 EMI56.1 EMI56.2 Prepn. SEP Rê SEP R SEP Amount SEP used SEP g SEP mmol. SEP Solvent SEP Reaction tb SEP No. SEP Compd. SEP IV SEP Compd. SEP V SEP ml SEP Time tb SEP hrs. tb SEP 32 SEP CH3 SEP SEP 1.90 41.3 SEP 6.05 40.0 SEP ethanol SEP 24 tb SEP 10 tb SEP 33 SEP CH3 SEP CH2 SEP 1.43 31.0 SEP 4.60 30.4 SEP ethanol SEP 15 tb SEP 8 tb Table 10 EMI57.1 Prepn. SEP RÚ SEP R SEP Yield SEP Melting SEP Point SEP NMR SEP ppmCDCl3 tb SEP No. SEP SEP C tb SEP CH3 SEP 71.7 SEP 173 174 SEP 0.90 277 11H,m , tb SEP 32 SEP SEP 3.43 2H,br,s , tb SEP 3.57 3H,s , tb SEP 5.32 1H,s tb SEP CH3 SEP 64.9 SEP 106 107 SEP 0.93 2.32 9H,m , tb SEP CH2 SEP 2.47 2H,m , tb SEP 33 SEP 3.51 3H,s , tb SEP 3.60 2H,br,s , tb SEP 5.28 1H,s tb